Comparative Cardiovascular Efficacy of SGLT2 Inhibitors, DPP-4 Inhibitors, and GLP-1 Agonists—A Network Meta-analysis

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 427-P
Author(s):  
ALISTAIR J. RODDICK ◽  
SEAN ZHENG
Keyword(s):  
Meta Analysis ◽  
Sglt2 Inhibitors

scholarly journals SGLT2 INHIBITORS DECREASE CARDIOVASCULAR MORTALITY OR HEART FAILURE HOSPITALIZATIONS IN HEART FAILURE SUBGROUPS: A SYSTEMATIC REVIEW AND META-ANALYSIS

2021 ◽  
Vol 77 (18) ◽  
pp. 655
Author(s):  
Rhanderson Cardoso ◽  
Fabrissio P. Graffunder ◽  
Caique M.P. Ternes ◽  
Gilson Fernandes ◽  
Ana Vitoria Rocha ◽  
...  
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Cardiovascular Mortality ◽  
Meta Analysis ◽  
Sglt2 Inhibitors

scholarly journals A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Junichi Mukai ◽  
Shinya Kanno ◽  
Rie Kubota
Keyword(s):  
Diabetes Mellitus ◽  
Meta Analysis ◽  
Japanese Patients ◽  
Sglt2 Inhibitors ◽  
Patients With Diabetes ◽  
Language Restriction ◽  
Calculated Risk ◽  
Favorable Safety ◽  
Type 1 Dm

AbstractThe safety profiles of sodium-glucose co-transporter 2 (SGLT2) inhibitors may depend on races/ethnicities. We aimed to assess the safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus (DM). The electronic databases MEDLINE, CENTRAL, and Ichushi-web were searched for studies with no language restriction from their inception to August 2019. Trials were included in the analysis if they were randomized controlled trials (RCTs) comparing the effects of SGLT2 inhibitors with a placebo in Japanese patients with DM > 18 years and reporting HbA1c and at least 1 adverse event. We calculated risk ratios with 95% CIs and used a random-effects model. Of the 22 RCTs included in our review, only 1 included patients with type 1 DM. The durations of RCTs ranged between 4 and 24 weeks. In comparison with a placebo, SGLT2 inhibitors were associated with similar risks of hypoglycemia, urinary tract infection, genital infection, hypovolemia, and fracture. The outcomes of treatment with SGLT2 inhibitors among Japanese patients with DM suggest favorable safety profiles. However, further evidence from studies with a longer duration, involving more diverse populations, such as patients with different types of DM, or including individual SGLT2 inhibitors is needed to resolve the limitations of the present study.

SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis

2021 ◽  
Author(s):  
Mahmoud Barbarawi ◽  
Ahmad Al-abdouh ◽  
Owais Barbarawi ◽  
Harini Lakshman ◽  
Mariam Al kasasbeh ◽  
...  
Keyword(s):  
Sequential Analysis ◽  
Meta Analysis ◽  
Sglt2 Inhibitors ◽  
Trial Sequential Analysis ◽  
Renal Outcomes

Meta‐analysis of the effect of SGLT2 inhibitors on hepatic fibrosis in patients with T2DM complicated with NAFLD

2021 ◽  
Author(s):  
Tiantian Song ◽  
Huan Song ◽  
Dongliang Tian ◽  
Fei Wang ◽  
Hang Zhao ◽  
...  
Keyword(s):  
Hepatic Fibrosis ◽  
Meta Analysis ◽  
Sglt2 Inhibitors

scholarly journals SGLT2 inhibitors and the risk of diabetic ketoacidosis among adults with Type 2 Diabetes: A systematic review and meta-analysis

2021 ◽  
Author(s):  
Michael Colacci ◽  
John Fralick ◽  
Ayodele Odutayo ◽  
Michael Fralick
Keyword(s):  
Diabetic Ketoacidosis ◽  
Observational Studies ◽  
Randomized Trials ◽  
Meta Analysis ◽  
Sglt2 Inhibitor ◽  
Sglt2 Inhibitors ◽  
Controlled Trials ◽  
Absolute Rate ◽  
Randomized Controlled

Importance: The risk of diabetic ketoacidosis (DKA) with sodium-glucose cotransporter-2 (SGLT2) inhibitors is unclear. Objective: To examine the risk of DKA with SGLT2 inhibitors in both observational studies and large clinical trials. Data Sources: Searches of PubMed, EMBASE and CENTRAL (inception to 15 April 2019) without language restrictions; conference proceedings; and reference lists. Study Selection: Randomized controlled trials and observational studies that quantified the rate of diabetic ketoacidosis with an SGLT2 inhibitor in comparison to another diabetes medication or placebo. Data Extraction and Synthesis: Two independent investigators abstracted study data and assessed the quality of evidence. Data were pooled using random effects models with the Hartung-Knapp-Sidik-Jonkman method. Main Outcome and Measures: Absolute event rates and hazard ratios for diabetic ketoacidosis were extracted from each study. Results: Seven randomized trials encompassing 42,375 participants and five cohort studies encompassing 318,636 participants were selected. Among the 7 randomized controlled trials, the absolute rate of DKA among patients randomized to an SGLT2 inhibitor ranged from 0.6 to 2.2 events per 1000 person years. Four randomized trials were included in the meta-analysis, and compared to placebo or comparator medication, SGLT2 inhibitors had a 2.4-fold higher risk of DKA (Relative Risk [RR] = 2.46 [95% CI, 1.16-5.21]; I2 = 0%; P = 0.54). Among the 5 observational studies, the absolute rate of DKA associated with SGLT2 inhibitor use ranged from 0.6 to 4.9 per 1000 person years and a 1.7-fold higher rate of DKA compared to another diabetes medication (RR = 1.74 [95% CI, 1.01-2.93]; I2 = 45%; P = 0.12). Conclusions and Relevance: In adults with type 2 diabetes, SGLT2 inhibitors increase the risk of DKA in both observational studies and large randomized clinical trials. Registration: CRD42019146855 Funding Source: None

Abstract #1088564: The Efficacy and Safety of a SGLT2 Inhibitors on Body Weight in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 27 (12) ◽  
pp. S6-S7
Author(s):  
Maria Kezia Pormento ◽  
Sivasthikka Lingarajah ◽  
Rajni Gautam ◽  
Molly Jain ◽  
Ravi Jagani ◽  
...  
Keyword(s):  
Systematic Review ◽  
Body Weight ◽  
Meta Analysis ◽  
Sglt2 Inhibitors ◽  
Obese Patients ◽  
Efficacy And Safety

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

The Lancet ◽  
2020 ◽  
Vol 396 (10254) ◽  
pp. 819-829 ◽  
Author(s):  
Faiez Zannad ◽  
João Pedro Ferreira ◽  
Stuart J Pocock ◽  
Stefan D Anker ◽  
Javed Butler ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Meta Analysis ◽  
Sglt2 Inhibitors ◽  
Reduced Ejection Fraction ◽  
Patients With Heart Failure
Sign in / Sign up

Export Citation Format

Share Document